AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23860273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22439653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation counselling (face-to-face visits weekly for the first four weeks, monthly to six months, and two monthly to 12 months) and encouragement to attend a monthly smoking cessation support group.
Number of subjects: 0
Study 22439653 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 20197741 — intervention group
Group type: EXPERIMENTAL
Intervention: Kouriles Acne
Number of subjects: 29
Study 18678295 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel (600 mg loading immediately before PCI and 75 mg 2 times/day for 1 month)
Number of subjects: 119
Study 18678295 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg loading and 75 mg/day)
Number of subjects: 119
Study 15620444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant
Number of subjects: 542
Study 15620444 — intervention group
Group type: COMPARATOR
Intervention: Control (routine intravenous antimicrobial prophylaxis)
Number of subjects: 542
Study 12560779 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein embolization (PVE) before right hepatectomy
Number of subjects: 55
Study 12560779 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery without PVE
Number of subjects: 55
Study 10379218 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (trimethoprim TMP‐SMZ, nitrofurantoin, or a quinolone)
Number of subjects: 0
Study 10379218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent patient‐administered treatment (taken at the onset of symptoms)
Number of subjects: 0
Study 10379218 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐term prophylaxis
Number of subjects: 0
Study 10379218 — intervention group
Group type: COMPARATOR
Intervention: Routine investigation of the urinary tract (excretory urography, ultrasonography, cystoscopy, voiding cystourethrography)
Number of subjects: 0
Study 8929005 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 2589
Study 8929005 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 2589
Study 2058162 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acids (8 capsules Ameu per day) for 21 days
Number of subjects: 0
Study 2058162 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acids (8 capsules Ameu per day) for 56 days
Number of subjects: 0
Study 6858170 — intervention group
Group type: EXPERIMENTAL
Intervention: Jopamidol
Number of subjects: 80
Study 6858170 — intervention group
Group type: COMPARATOR
Intervention: Meglumine iodamine
Number of subjects: 80
Study 30387697 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion at a threshold of 50,000 per cubic millimeter (high-threshold group)
Number of subjects: 660
Study 30387697 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusion at a threshold of 25,000 per cubic millimeter (low-threshold group)
Number of subjects: 660
Study 30387697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threshold group
Number of subjects: 660
Study 30387697 — intervention group
Group type: COMPARATOR
Intervention: Low-threshold group
Number of subjects: 660
Study 29914484 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-playing simulation (experimental group)
Number of subjects: 0
Study 29914484 — intervention group
Group type: COMPARATOR
Intervention: Lecture on TPE (comparison group)
Number of subjects: 0
Study 26565005 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg lovastatin for 5 days
Number of subjects: 300
Study 26565005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24571189 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 186
Study 24571189 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 186
Study 20665751 — intervention group
Group type: EXPERIMENTAL
Intervention: SSc patients
Number of subjects: 25
Study 20665751 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse cutaneous SSc subgroup
Number of subjects: 25
Study 19861267 — intervention group
Group type: EXPERIMENTAL
Intervention: PFVA and TEAS at Hegu‐Laogong and Neiguan‐WaiGuan acupoints (Group B)
Number of subjects: 90
Study 19861267 — intervention group
Group type: EXPERIMENTAL
Intervention: PFVA and TEAS at Hegu‐Laogong, Neiguan‐Waiguan, and bilateral Jianjing acupoints (Group C)
Number of subjects: 90
Study 19861267 — intervention group
Group type: COMPARATOR
Intervention: PFVA (Group A)
Number of subjects: 90
Study 17718820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) at doses of 12.5 microg, 20 microg, 25 microg, and 50 microg.
Number of subjects: 17
Study 17718820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17718820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 17
Study 15733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard heparin (n = 37)
Number of subjects: 107
Study 15733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (n = 31)
Number of subjects: 107
Study 15733401 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 107
Study 11680354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine plain
Number of subjects: 310
Study 11680354 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with 1:100,000 epinephrine
Number of subjects: 310
Study 9709279 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening offered
Number of subjects: 0
Study 9709279 — intervention group
Group type: COMPARATOR
Intervention: No breast cancer screening offered (control)
Number of subjects: 0
Study 7886187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.83 ml ethanol/kg body weight)
Number of subjects: 16
Study 7886187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2838344 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (0.01‐5 micrograms/ml)
Number of subjects: 0
Study 30262887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (48 IU/day)
Number of subjects: 17
Study 30262887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (200 ng/100 μL/mouse, for 14 consecutive days)
Number of subjects: 17
Study 30262887 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Oxytocin (200 ng/100 μL/mouse, once)
Number of subjects: 17
Study 30262887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29907608 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS (gammaCore)
Number of subjects: 248
Study 29907608 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 248
Study 27145524 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-neck pacifier (TNP)
Number of subjects: 86
Study 27145524 — intervention group
Group type: COMPARATOR
Intervention: Conventional or physiological pacifier (Control)
Number of subjects: 86
Study 27145524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard, weaned off pacifier
Number of subjects: 86
Study 24574227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 24574227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22736271 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE: Creating Avenues for Relative Empowerment, a two-session empowerment-educational program 1-2 days post-admission and 1-3 days pre-discharge
Number of subjects: 407
Study 22736271 — intervention group
Group type: COMPARATOR
Intervention: Attention control group, received a generic information program during the same timeframe
Number of subjects: 407
Study 20407113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated sheaths
Number of subjects: 35
Study 20407113 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated sheaths
Number of subjects: 35
Study 20407113 — intervention group
Group type: COMPARATOR
Intervention: Noncatheterized arm
Number of subjects: 35
Study 18854748 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based treatment
Number of subjects: 5137
Study 18854748 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 5137
Study 16097419 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCAB
Number of subjects: 20
Study 16097419 — intervention group
Group type: COMPARATOR
Intervention: OFFCAB
Number of subjects: 20
Study 16097419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 11837547 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 11837547 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 10512261 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 1 mg IV and meperidine 50 mg
Number of subjects: 90
Study 10512261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-6791 0.5 mg IV and meperidine 50 mg
Number of subjects: 90
Study 10512261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-6791 1.0 mg IV alone
Number of subjects: 90
Study 10512261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-6791 (both doses)
Number of subjects: 90
Study 10512261 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 7717282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg 3 times daily)
Number of subjects: 64
Study 7717282 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg once daily)
Number of subjects: 64
Study 7717282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2251022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine-adrenaline-cocaine (TAC)
Number of subjects: 55
Study 2251022 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline-cocaine
Number of subjects: 55
Study 6988170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g by intravenous injection prior to induction of anaesthesia)
Number of subjects: 47
Study 6988170 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 47
Study 31750691 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship program (online self-help relationship intervention)
Number of subjects: 600
Study 31750691 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship program
Number of subjects: 600
Study 31750691 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 600
Study 31514453 — intervention group
Group type: COMPARATOR
Intervention: Frankel's stabilization exercises (C)
Number of subjects: 40
Study 31514453 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilometric platform (E)
Number of subjects: 40
Study 28554517 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum injection
Number of subjects: 832
Study 25826376 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation and learning opportunities
Number of subjects: 422
Study 25826376 — intervention group
Group type: EXPERIMENTAL
Intervention: Height for age
Number of subjects: 422
Study 25826376 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight for height z-scores
Number of subjects: 422
Study 25826376 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of days with diarrhea
Number of subjects: 422
Study 23819903 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive support (6 educational sessions focused on behavior change strategies and motivation with nutrition counseling)
Number of subjects: 144
Study 23819903 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study 22040192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25-150 mg/day)
Number of subjects: 26
Study 22040192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20127533 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 0.25% levobupivacaine (LB group)
Number of subjects: 40
Study 20127533 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS group)
Number of subjects: 40
Study 16570766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 16570766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 16570766 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 16570766 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise only
Number of subjects: 0
Study 12429673 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational training package for primary health care teams in accident prevention
Number of subjects: 1666
Study 12429673 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 1666
Study 10473477 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug counselling
Number of subjects: 250
Study 10473477 — intervention group
Group type: COMPARATOR
Intervention: Treatment leaflets
Number of subjects: 250
Study 10473477 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling for patients with major depressive disorder receiving doses >=75 mg
Number of subjects: 250
Study 10473477 — intervention group
Group type: COMPARATOR
Intervention: No counselling for patients with major depressive disorder receiving doses >=75 mg
Number of subjects: 250
Study 8758157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-induced spinal block
Number of subjects: 105
Study 8758157 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular bupivacaine 12.5 mg
Number of subjects: 105
Study 1956009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hulka clip application
Number of subjects: 50
Study 1956009 — intervention group
Group type: COMPARATOR
Intervention: Modified Pomeroy tubal ligation
Number of subjects: 50
Study 6918920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 2 liters per minute for 30 minutes
Number of subjects: 100
Study 6918920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 4 liters per minute for 30 minutes
Number of subjects: 100
Study 6918920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 6 liters per minute for 30 minutes
Number of subjects: 100
Study 6918920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxygen inhalation)
Number of subjects: 100
Study 31876454 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in heat (37.41°C)
Number of subjects: 13
Study 31876454 — intervention group
Group type: COMPARATOR
Intervention: Standing in heat (37.56°C)
Number of subjects: 13
Study 31876454 — intervention group
Group type: COMPARATOR
Intervention: Exercise in ambient temperature (14.24°C)
Number of subjects: 13
Study 30782008 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD intervention (the Sleep Easy Solution)
Number of subjects: 239
Study 28448664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg intravitreous bevacizumab
Number of subjects: 61
Study 28448664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg intravitreous bevacizumab
Number of subjects: 61
Study 28448664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.063 mg intravitreous bevacizumab
Number of subjects: 61
Study 28448664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.031 mg intravitreous bevacizumab
Number of subjects: 61
Study 26393847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan-quinidine
Number of subjects: 220
Study 26393847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 24108114 — intervention group
Group type: EXPERIMENTAL
Intervention: Profermin
Number of subjects: 74
Study 24108114 — intervention group
Group type: COMPARATOR
Intervention: Fresubin
Number of subjects: 74
Study 21339632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of human rhGH administered from day 1 to day 7
Number of subjects: 30
Study 21339632 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo) administered from day 1 to day 7
Number of subjects: 30
Study 19411369 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release
Number of subjects: 399
Study 19411369 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 399
Study 19411369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 17426626 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted tool for brace design and adjustment
Number of subjects: 48
Study 17426626 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for brace design and adjustment
Number of subjects: 48
Study 15956509 — intervention group
Group type: EXPERIMENTAL
Intervention: 6F Closer S device (Perclose)
Number of subjects: 416
Study 15956509 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 416
Study 15956509 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review
Number of subjects: 416
Study 11791086 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (estradiol 2 mg and norethisterone acetate 1 mg)
Number of subjects: 22
Study 11791086 — intervention group
Group type: COMPARATOR
Intervention: Control group (clodronate only)
Number of subjects: 22
Study 11791086 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group
Number of subjects: 22
Study 10604491 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan once daily
Number of subjects: 69
Study 10604491 — intervention group
Group type: COMPARATOR
Intervention: 25 mg HCTZ once daily
Number of subjects: 69
Study 7781871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of ipriflavone and 1 alpha vitamin D
Number of subjects: 98
Study 7781871 — intervention group
Group type: COMPARATOR
Intervention: Ipriflavone alone
Number of subjects: 98
Study 7781871 — intervention group
Group type: COMPARATOR
Intervention: 1 alpha vitamin D alone
Number of subjects: 98
Study 7781871 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 98
Study 1933081 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory notebook training
Number of subjects: 4
Study 7039755 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 190
Study 7039755 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucagon)
Number of subjects: 190
Study 30912690 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 45 min, once a week
Number of subjects: 60
Study 30912690 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 15 min, three times a week
Number of subjects: 60
Study 30912690 — intervention group
Group type: COMPARATOR
Intervention: Usual care Control Group
Number of subjects: 60
Study 30346913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the primary motor cortex
Number of subjects: 19
Study 30346913 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 19
Study 29704398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 11
Study 29704398 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 11
Study 29704398 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 11
Study 26858122 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg
Number of subjects: 102
Study 26858122 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg
Number of subjects: 102
Study 26858122 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 weeks, or 10 mg/kg every 2 weeks, plus tremelimumab 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 weeks for six doses then every 12 weeks for three doses
Number of subjects: 102
Study 24671340 — intervention group
Group type: EXPERIMENTAL
Intervention: nalmefene 18 mg/day
Number of subjects: 675
Study 24671340 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 675
Study 23206762 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous nephrolithotomy with the aid of a patented system
Number of subjects: 182
Study 23206762 — intervention group
Group type: COMPARATOR
Intervention: Transurethral ureteroscopy
Number of subjects: 182
Study 20703211 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 36
Study 20703211 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine (CsA)
Number of subjects: 36
Study 20703211 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate sodium (MPA)
Number of subjects: 36
Study 20703211 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone (P) plus CsA
Number of subjects: 36
Study 20703211 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone (P) plus MPA
Number of subjects: 36
Study 20703211 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone (P) plus everolimus
Number of subjects: 36
Study 18372684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial mechanical loading (2.5 G at the feet decreasing to 1 G at the heart) for 60 min daily during 21 days of head-down bed rest
Number of subjects: 0
Study 18372684 — intervention group
Group type: COMPARATOR
Intervention: Control group (instrumented but did not receive centrifugation)
Number of subjects: 0
Study 16404960 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified endoscopic surgical procedure by J. Destandau
Number of subjects: 58
Study 16404960 — intervention group
Group type: COMPARATOR
Intervention: Routine endoscopic surgical procedure
Number of subjects: 58
Study 11966384 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative care
Number of subjects: 691
Study 9619219 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 24
Study 9619219 — intervention group
Group type: EXPERIMENTAL
Intervention: IRV
Number of subjects: 24
Study 9619219 — intervention group
Group type: COMPARATOR
Intervention: Manual inflations
Number of subjects: 24
Study 9619219 — intervention group
Group type: COMPARATOR
Intervention: Large tidal volumes
Number of subjects: 24
Study 9619219 — intervention group
Group type: COMPARATOR
Intervention: Pressure control IRV
Number of subjects: 24